Additionally, the pre-meiotic marker Sall4 and the meiotic marker CREM were significantly increased (quantity and expression levels) following GCSF treatment of the AML- and/or CYT-treated groups. The gene discussed is SALL4; the disease is acute myeloid leukemia.